Methodology
Methodology in Practice
Not a prediction. A worked example — how cross-domain synthesis and disciplined method surface questions that single-source analysis misses.
What follows is a single situation, analysed the way Continuum analyses every position in your portfolio, every day.
The Situation
A top-four grocery retailer. Fifteen years of earnings growth built on private label expansion and property leverage. Premium valuation at 22× forward — 20% above sector — pricing a return to historical margins after two years of competitive disruption from a discount entrant now operating 600+ stores nationally. Management’s response: “investing through the cycle” with $1.2 billion in supply chain capex.
A composite drawn from recurring patterns across Australian equities.
Priced Narrative
Margins recover as competitive intensity normalises
Market assumes the discount entrant reaches natural scale limits and the incumbent restores pricing power within two years.
Implied Requirement
Competitor share gains decelerate; margins restore by FY27
At 22× forward, the price requires EBIT margins above 5.3% within two years. Current run rate: 4.8% and declining.
The question is not whether this is a good company. It is. The question is whether the assumptions embedded in this price can survive contact with evidence from eight independent domains.
Cross-Domain Synthesis
Eight evidence domains. Different motivations, different reliability, different incentive structures. A CEO has every reason to guide optimistically. A regulator has no reason to exaggerate concern. A competitor filing a 4E has no reason to understate their own momentum. Where independent sources converge, confidence is warranted. Where they diverge, the divergence is the signal.
Corporate Communications
Guides to margin recovery by FY27. Confident tone. Digital positioned as tailwind. Supply chain investment framed as “building for the next decade.”
Guidance missed 3 of 4 years. Track record undermines forward claims.
Regulatory Filings
ACCC interim report notes “pricing practices of concern.” Flags potential structural remedies. Commissioner’s public comments suggest scope widening beyond initial terms of reference.
Outcome range wider than the market is pricing.
Supply Chain & Procurement
Three key suppliers have publicly guided to maintaining pricing. Supplier filings show input cost renegotiations failing to achieve target reductions. Private label margin assumptions depend on procurement savings that suppliers are not conceding.
Cost recovery assumption contradicted by the other side of the negotiation.
Competitor Disclosures
Discount competitor’s 4E shows share gains accelerating quarter-on-quarter. Capex guidance increased. Explicitly targets the premium segment as “structurally vulnerable to value migration.”
The market assumes normalisation. The competitor is planning intensification.
Economic Data
Category growth decelerating. Consumer sentiment below long-run average. Household budgets under pressure from mortgage resets and insurance costs. Discretionary wallet share contracting.
Macro environment doesn’t support “return to normal” consumer behaviour.
Alternative Data
SEEK postings: hiring in ops and logistics, cuts in corporate and marketing. Web traffic up but conversion metrics suggest online channel remains dilutive to margins. Foot traffic data shows trade-down patterns persisting.
Actions suggest cost management mode, not growth investment.
Academic Research
Literature on “price investment to defend share” shows margins rarely recover to prior levels. Post-inflationary consumer price sensitivity persists 3–5 years. Structural share shifts in grocery tend to be permanent.
Base rate for recovery is lower than the narrative implies.
Media & Political
“Cost of living” framing intensifying ahead of election cycle. Grocery pricing now a political issue. ACCC inquiry gaining salience with both major parties signalling willingness to act.
Regulatory risk is underappreciated because it sits outside financial models.
Of eight independent evidence domains, seven contradict or fail to support the priced narrative. The one that supports it — corporate communications — has missed its own guidance three of the last four years.
Evidence Alignment
How each domain relates to the priced narrative: “Margins recover by FY27”
Competing Hypotheses
The natural instinct is to form a view and look for evidence that supports it. The problem is well-documented: once you hold a position, you process new information through that lens. Disconfirming evidence gets rationalised. Confirming evidence gets amplified. The thesis survives contact with reality longer than it should.
Generating competing hypotheses forces a different question — not “am I right?” but “which interpretation has survived the most attempts to disprove it?” We generate four distinct futures and test each against evidence.
Stability
Priced scenarioCompetitive intensity normalises. Cost programs deliver. Premium valuation justified by defensive characteristics and eventual margin recovery.
Requires: Competitor share gains <0.5% p.a. No material regulatory intervention. Margin ≥5.3% by FY27.
Acceleration
Least evidenceDigital transformation delivers margin expansion beyond historical levels. Supply chain capex generates returns ahead of schedule. Market underestimates business quality.
Requires: Digital channel profitability. Cost savings exceeding guidance. Gross margin expansion despite competitive pressure.
Structural Compression
Evidence accumulatingCompetitive pressure is permanent, not cyclical. Price investment becomes the new baseline. Margins settle 50–100bps below historical average. Premium valuation unsustainable at these economics.
Requires: Competitor share gains at current pace. Consumer price sensitivity persists. Supplier cost inflation not recoverable.
Regulatory Intervention
Tail riskACCC inquiry leads to structural remedies — divestiture, pricing constraints, or mandatory code of conduct with compliance costs. Industry profitability impaired across all participants.
Requires: Structural remedies recommended. Government acts before election. Material compliance costs or pricing restrictions imposed.
What Settles It
Most evidence is noise. Revenue grew 3.8% — consistent with all four hypotheses. Management expressed confidence — expected regardless. The real question is: which evidence would look different depending on which hypothesis is true? That’s discriminating evidence, and it’s the only evidence that should update your assessment.
This distinction — between evidence that feels informative and evidence that actually discriminates — is where most analysis fails. A research note full of data points that are consistent with every scenario has told you nothing.
Discriminating Evidence
Evidence that would look different depending on which hypothesis is true.
Competitor share gains accelerating
Margin guidance missed 3 of 4 years
ACCC interim report flags structural concerns
Supplier filings: input renegotiations failing
Academic: price investment rarely reverses
Evidence that doesn’t discriminate
Data points that feel relevant but are consistent with all scenarios — and therefore update nothing.
Evidence Weight by Hypothesis
Thesis 3 has the most independent evidentiary support. Thesis 1 is priced but not evidenced.
What We’re Watching
We don’t conclude which hypothesis is correct. We specify — in advance — what would change our assessment and when we’ll know. The conditions are defined before the data arrives, not after, because that’s the only way to prevent rationalisation once the numbers are in front of you.
Decision Points
Three events will discriminate between hypotheses. We specify the test before the data arrives.
- Next reporting season
Half-year results
Tests:
Margin ≥5.3% → 1 ↑
Margin <5.0% → 3 ↑
- Competitor quarterly
4E filing + trading update
Tests:
Share deceleration → 1 ↑
Share acceleration → 3 ↑
- ACCC final report
Regulatory decision
Tests:
Behavioural only → 1 ↑
Structural remedies → 4 ↑
- Next reporting season
Half-year results
Tests:
Margin ≥5.3% → 1 ↑
Margin <5.0% → 3 ↑
- Competitor quarterly
4E filing + trading update
Tests:
Share deceleration → 1 ↑
Share acceleration → 3 ↑
- ACCC final report
Regulatory decision
Tests:
Behavioural only → 1 ↑
Structural remedies → 4 ↑
Strengthens if
Strengthens if
Crystallises if
This is where analysis ends: not with conviction, but with clarity about what we’re testing and what would change our view.
From Manual to Continuous
This analysis took a team of three analysts four weeks to assemble manually for a single name. Reading across eight domains, cross-referencing supplier filings with corporate guidance, testing each data point against four hypotheses, defining revision conditions in advance. Rigorous, valuable — and impossible to maintain across thirty positions simultaneously.
Continuum maintains it continuously across the full portfolio. Not by cutting corners — by reading everything, systematically, and never forgetting what it found yesterday when new evidence arrives today. When a supplier files a quarterly update that contradicts a portfolio company’s margin guidance, the connection is made within minutes, not weeks.
The method is the same. The scale is what changes.
See the platform that makes this operational.
Monitor your positions. Discover new ideas. Analyse any name. Continuously.
Continuum is in private access with select institutional investors.